 Home > Active Ingredient News > Drugs Articles > Pioneer Pharmaceuticals and Etana reached a partnership on the commercialization of Prokalamide in the treatment of COVID-19 in Indonesia

Pioneer Pharmaceuticals and Etana reached a partnership on the commercialization of Prokalamide in the treatment of COVID-19 in Indonesia

 Last Update: 2021-09-13
 Source: Internet
 Author: User

Tags

land use united states

angiotensin receptor antagonist

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On August 25th, Pioneer Pharmaceuticals announced that it has reached a cooperation agreement with Indonesian biotech company Etana Biotechnologies (Etana) on the commercialization of prokulamide in the treatment of COVID-19 in Indonesia (hereinafter referred to as "Indonesia")
.

According to the agreement, Kaifeng Pharmaceutical will receive a down payment and milestone payment from Etana.
In addition, it will also receive economic benefits related to the sale of prokruamide in Indonesia.
The transaction is in line with industry practices
.

Prokalamide is a new generation of androgen receptor antagonist independently developed by Kaixing Pharmaceutical.
Since the pandemic of the new crown epidemic in early 2020, Kaixing Pharmaceutical has rapidly started research on the use of procluamide for the treatment of new crowns
.

At present, procrulamide is undergoing three global multi-center phase III clinical trials of new crown treatment in the United States, South America (including Brazil), the European Union, Asia and other countries and regions, and was granted the first emergency use authorization by Paraguay in July 2021 (EUA)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.